Age, GVHD prophylaxis, and timing matter in thrombotic microangiopathy after haematopoietic cell transplantation—A secondary CIBMTR analysis
British Journal of Haematology · 2024
DOI: 10.1111/bjh.19506 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift British Journal of Haematology, 2024. Verfasst von Michelle L Schoettler und 6 weiteren Autor:innen. Beteiligte Einrichtung: Aflac Cancer and Blood Disorders Center, Children's Healthcare of Atlanta, Emory University, Atlanta, Georgia, USA. Hauptthemen laut MEDLINE: Hematopoietic Stem Cell Transplantation, Graft vs Host Disease, Thrombotic Microangiopathies. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, Center for Strategic Scientific Initiatives, National Cancer Institute, ASH Foundation, Robert Wood Johnson Foundation.
Abstract (Originalsprache)
Most reports of risk factors (RF) for developing transplant‐associated thrombotic microangiopathy (TA‐TMA) and death are derived from paediatric and young adult cohorts, with minimal data on differences in RF and outcomes by age. In this secondary CIBMTR analysis, we used a previously prepared dataset that included all first allogenic haematopoietic cell transplantation (HCT) recipients with malignant or non‐malignant diseases between 2008 and 2016. The incidence of TA‐TMA 6 months post HCT was similar in children and adults 2.1% and 2.0% respectively. Grade 2–4 acute graft‐versus‐host disease (aGVHD) was a significant adjusted RF for developing TA‐TMA in both children and adults. In adults, additional adjusted RFs for TA‐TMA included female sex and black race, and in children an unrelated donor. Compared to a calcineurin inhibitor and sirolimus, other forms of GVHD prophylaxis had an adjusted decreased risk of developing TA‐TMA in adults. Adjusted RF for death in those with TA‐TMA ( n = 652) included age ≥18 years old, early onset of TA‐TMA diagnosis (
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Aflac Cancer and Blood Disorders Center, Children's Healthcare of Atlanta, Emory University, Atlanta, Georgia, USA.
- Pediatric Biostatistics Core, Department of Pediatrics, Emory University, Atlanta, Georgia, USA.
- Children's Hospital, New Orleans, Tulane Pediatric Hematology/Oncology, New Orleans, Louisiana, USA.
ORCID-Profile: Michelle L Schoettler, Satheesh Chonat
Förderung
- NCI NIH HHS
- Center for Strategic Scientific Initiatives, National Cancer Institute
- ASH Foundation, Robert Wood Johnson Foundation
- ASH Foundation
Zitieren
APA
Schoettler, M. L., Westbrook, A., Watkins, B., Stenger, E., Qayed, M., Chonat, S., & Williams, K. M. (2024). Age, GVHD prophylaxis, and timing matter in thrombotic microangiopathy after haematopoietic cell transplantation—A secondary CIBMTR analysis. British Journal of Haematology. https://doi.org/10.1111/bjh.19506
Vancouver
Schoettler ML, Westbrook A, Watkins B, Stenger E, Qayed M, Chonat S, et al. Age, GVHD prophylaxis, and timing matter in thrombotic microangiopathy after haematopoietic cell transplantation—A secondary CIBMTR analysis. British Journal of Haematology. 2024. doi:10.1111/bjh.19506
BibTeX
@article{Schoettler2024,
author = {Schoettler, Michelle L and Westbrook, Adrianna and Watkins, Benjamin and Stenger, Elizabeth and Qayed, Muna and Chonat, Satheesh and Williams, Kirsten M},
title = {Age, GVHD prophylaxis, and timing matter in thrombotic microangiopathy after haematopoietic cell transplantation—A secondary CIBMTR analysis},
journal = {British Journal of Haematology},
year = {2024},
doi = {10.1111/bjh.19506}
}
EUVIMED